The Multiple Sclerosis Partnering provides understanding and access to the multiple sclerosis partnering deals and agreements entered into by the worlds leading healthcare companies
Merger news: Rumors that Ireland-based Actavis is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV.
By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.
This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.
Abbvie has acquired only one company in 2010 with the purchase of Facet Biotechnology valued at $722 million.
This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.
Sorry, your search returned no results.
This second collaboration between the two companies follows a previous agreement announced in 2007 to develop ARX201, Ambrx’s long-acting growth hormone product, currently in Phase II of clinical development.
Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467.
Receptos announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $100.00 per share
AstraZeneca, MedImmune has entered into four new biotech partnering with the University of Cambridge, building further on their existing partnership.
DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million.
The National Multiple Sclerosis Society has committed another $29 million to support an expected 83 new MS research projects and training awards.